The Coriell Institute for Medical Research Welcomes Two New Scientists to Expanding Research Team

11/2026

The Coriell Institute for Medical Research Welcomes Two New Scientists to Expanding Research Team

Huda Salman and Rexxi Prasasya establish new laboratories focused on cancer immunotherapy and epigenetics 

CAMDEN, N.J. — The Coriell Institute for Medical Research is pleased to announce two new scientists joining its growing research team: Huda Salman, MD, PhD, and Rexxi Prasasya, PhD. Both researchers will lead new laboratories at Coriell, bringing expertise in cancer immunotherapy, epigenetics, and reproductive biology while further strengthening the Institute's commitment to advancing biomedical research.

Adding these two laboratories represents another important step in expanding Coriell's research capabilities. While their areas of expertise differ, both scientists are pursuing research to better understand the biological mechanisms underlying human disease.

“Attracting scientists of this caliber is central to Coriell’s future,” said Jean-Pierre Issa, MD, president and chief executive officer of Coriell. “Huda and Rexxi bring complementary expertise, and with our partners at Cooper Norcross Health, we are building a research community in Camden that can compete nationally. We are proud to have them on our team.”

Salman brings extensive experience in hematologic cancers and cellular immunotherapy, with a particular focus on developing new treatments for difficult-to-treat malignancies. Her laboratory will investigate next-generation chimeric antigen receptor (CAR) T-cell therapies, which involve engineering immune cells to better recognize and attack cancer. In partnership with Cooper Norcross Health, Salman will work to bridge laboratory discoveries and clinical applications, drawing on the two institutions' shared commitment to advancing cancer research through the Camden Cancer Research Center (CCRC).

“Coriell offers a rare combination of scientific rigor, collaborative spirit, and a close connection to the community it serves,” said Salman. “I’m excited to establish my laboratory here and to advance next-generation CAR T-cell therapies for hard-to-treat blood cancers. Working with our partners at Cooper Norcross Health through the CCRC, we can move more directly from the laboratory bench toward the clinic, with the goal of bringing new options to patients.”

Before joining Coriell, Salman served as the inaugural Executive Director of the Brown Center for Immunotherapy at Indiana University School of Medicine, where she led efforts to advance cellular immunotherapy research and its clinical applications. She previously held leadership positions at Stony Brook University, including Section Chief of Hematological Malignancies and Director of the CAR T-Cell Program. Her work includes developing a first-in-human CD4-directed CAR T-cell therapy program targeting T-cell cancers. Salman earned her medical and doctoral degrees from the University of Jordan and completed additional clinical and research training in New York.

Prasasya joins Coriell with a research background in developmental biology and epigenetics, the study of how chemical modifications influence gene activity without changing the underlying DNA sequence. Her laboratory will investigate how DNA methylation patterns are established during reproductive cell development and how disruptions to these processes can contribute to disease, particularly cancer. Her research will also explore how fundamental discoveries in epigenetics can improve understanding of fertility and women's reproductive health.

“Some of the most important questions in biology come down to how a cell knows which genes to switch on, and how that memory is set in the first place,” said Prasasya. “At Coriell, I have the freedom and the resources to pursue those questions in reproductive cells, where the stakes for fertility and for diseases like cancer are so high. I’m eager to get started and to find the collaborations across the Institute that will push this work further.”

Before joining Coriell, Prasasya conducted research at the University of Pennsylvania's Perelman School of Medicine, where she investigated epigenetic regulation and genomic imprinting, a process that influences whether certain genes are expressed based on their parent of origin. Her research examined how reproductive cells establish the epigenetic identities necessary for fertility, including the discovery that the TET1 enzyme plays an unexpected role in directing DNA methylation in reproductive cells. Prasasya earned her degrees from the University of Wisconsin–Madison and Northwestern University. Her training spans cellular signaling, reproductive biology, and epigenetic regulation.

The arrival of both scientists broadens Coriell’s research portfolio and creates new opportunities for cross-disciplinary collaboration. Their work will complement existing efforts at the Institute, and Coriell looks forward to supporting them as they establish their laboratories and build new collaborations aimed at improving human health.
###
For the past 73 years, in pursuit of preventing and curing diseases, Coriell scientists have conducted groundbreaking research in infectious diseases, genetic diseases, cancer, aging, and personalized medicine. Coriell has also pioneered research-accelerating biomaterials by establishing and curating key biobanks that now contain some of the world's most extensive collections of cell lines, DNA, and other biomaterials, gathered and distributed for use by the international research community. Coriell holds one of the first two official cell banks recognized by the National Institutes of Health (NIH) in 1960. Coriell currently hosts biobanks for the following NIH institutes: NIGMS, NINDS, NHGRI, NEI, and NIA. In addition to its biobanks, Coriell researchers study aging, cancer, stem cells, epigenomics, and pharmacogenomics, among other topics. Many projects, such as the longstanding Camden Opioid Research Initiative (CORI) and the Camden Cancer Research Center (CCRC), focus on the historically underserved city of Camden and Southern New Jersey.

Other News